Breast cancer is the most frequent malignancy in females. Due to its major impact on
population, this disease represents a critical public health problem that requires further …

The successful use of high dose synthetic estrogens to treat post-menopausal metastatic
breast cancer, is the first effective “chemical therapy” proven in clinical trial to treat any …

It is 45 years since a pleural effusion from a patient with metastatic breast cancer led to the
generation of the MCF-7 breast cancer cell line. MCF-7 is the most studied human breast …

Background: Tamoxifen (TAM) is the main treatment of estrogen receptor (ER)-positive
breast cancer, however; its adverse effects and development of resistance hinder its use …

The in vitro anticancer efficacy of a new series of quinazoline-based thiazole derivatives was
explored. Three cancer cell lines, MCF-7, HepG2, and A548, as well as the normal Vero cell …

Breast cancer stem cells (BCSC) play critical roles in the acquisition of resistance to
endocrine therapy in estrogen receptor (ER)-positive (ER+ ve) breast cancer (BC). The …

Common recommendations for cell line authentication, annotation and quality control fall
short addressing genetic heterogeneity. Within the Human Toxome Project, we demonstrate …

The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …

Estrogen receptor alpha (ERα) is a ligand-dependent master transcriptional regulator and
key driver of breast cancer pathology. Small molecule hormones and competitive …

The epithelial splicing regulatory proteins 1 and 2 (ESRP 1 and ESRP 2) control the
epithelial‐to‐mesenchymal transition (EMT) splicing program in cancer. However, their role …